PARP inhibitors are a specific category of cancer drugs designed to target and destroy cancer cells. They operate by blocking poly adenosine diphosphate-ribose polymerase (PARP), an enzyme instrumental in repairing DNA damage within cells. By inhibiting PARP, these drugs deter cancer cells from repairing themselves, leading to their eventual death. This targeted therapeutic approach primarily focuses on cancer cells, minimizing adverse effects on healthy cells.
This article delves into the operation and applications of PARP inhibitor targeted therapy while outlining potential side effects and key considerations.
PARP inhibitors are prescription drugs used in the treatment of specific cancer types. They function by blocking PARP enzymes within cells. These enzymes are crucial for repairing DNA damage, and by inhibiting them, cancer cells are prevented from self-repair, ultimately leading to their death.
Currently, there are four primary PARP inhibitors on the market. These drugs inhibit the activity of PARP-1, PARP-2, and PARP-3, all of which assist in repairing cell DNA damage. By preventing the cancer cells from repairing themselves, these drugs lead to the death of the cancer cells. Furthermore, these drugs are specifically engineered to target cancer cells. There are ongoing developments in the pharmaceutical industry for more precise PARP inhibitors that can zero in on tumor cells.
The Food and Drug Administration (FDA) has given its approval for the use of PARP inhibitors in certain cancer treatments. Rucaparib, for instance, is utilized in treating specific types of ovarian, fallopian tube, primary peritoneal, and prostate cancer. It is generally prescribed when other treatments like chemotherapy have been ineffective or during the maintenance period post-chemotherapy.
Niraparib bears similar applications to rucaparib, primarily for ovarian cancer, fallopian tube cancer, and primary peritoneal cancer, but not for prostate cancer. Doctors typically prescribe niraparib following at least three chemotherapy sessions. Recent studies also endorse its use as a maintenance treatment after first-line chemotherapy.
Olaparib has the broadest range of applications. In addition to treating ovarian, fallopian tube, and primary peritoneal cancer, it can also treat BRCA-associated metastatic breast cancer.
Prior to starting treatment, it’s crucial to discuss potential side effects and interactions of any PARP inhibitor with a healthcare professional. They can offer guidance on managing side effects, actions to take if side effects become severe, and circumstances under which treatment should be halted.
Patients should inquire about label warnings and any associated risks. Additionally, doctors can provide insights on the drug’s efficacy in treating similar cancer cases, often referred to as the “effectiveness of the treatment.” It’s also important to inform the doctor of any other medications, remedies, or supplements being taken, as they could potentially interfere with the efficacy and safety of PARP inhibitors.
In conclusion, PARP inhibitors function by disrupting enzymes that aid in the repair of cancer cells. By blocking these enzymes, cancer cells are unable to repair, resulting in their death. These inhibitors are a type of targeted therapy that primarily affects cancer cells, causing fewer side effects on healthy cells compared to traditional chemotherapy. They are often prescribed for treating ovarian, fallopian tube, primary peritoneal, breast, prostate, or pancreatic cancer. Currently, four such drugs are available, and more are under development.